Increases seen in overdose deaths from opioids, as well as cocaine and psychostimulants
Neither Remdesivir Nor HCQ Affect Viral Clearance in COVID-19
No significant difference seen for in-hospital mortality among those receiving remdesivir, hydroxychloroquine, standard of care
Pfizer-BioNTech COVID-19 Vaccine Safe, Effective in Cancer Patients
Pronounced lag in antibody production after the first dose found versus noncancer controls
WHO: Get COVID-19 Vaccines to Poor Nations Instead of Making Booster Shots
Advocacy group ONE Campaign says only 1 percent of people in poor countries have received even one COVID-19 vaccine dose
Pfizer Presses U.S. Scientists, Officials on Third Booster Shot
U.S. officials say that more data are needed before regulators can determine whether booster shots are necessary
U.S. NIH Turbo Charges India’s COVID-19 Vaccine
An adjuvant developed with funding from the National Institutes of Health (NIH) has contributed to the success of the Covaxin COVID-19 vaccine, which roughly 25 million people have already received in India and elsewhere.
Adjuvants are substances formulated as part of a vaccine to boost immune responses and enhance a vaccine’s effectiveness. Covaxin was developed and is manufactured in India by Bharat Biotech, stated the NIH on June 29, 2021.
Can Genetics Tackle COVID-19 with Drug Repurposing
Each SARS-CoV-2 betacoronavirus infection has variable severities in people, ranging from asymptomatic to severe life-threatening respiratory failure, coagulation, or neurological symptoms, among other sequelae, said genomics researchers in a blog posting on July 7, 2021.
These individual-level responses to infection have led scientists to investigate the effects of genetic variation in the human genome that may explain the broad spectrum of COVID-19 severity and susceptibility, continues the article.
ACIP: Benefits of mRNA COVID-19 Vaccines Outweigh Risks for ≥12s
After reviewing evidence, including data on risks for myocarditis, vaccination benefits outweigh risks for all populations
FDA Adds Guillain-Barré Warning to J&J COVID-19 Vaccine
About 100 preliminary reports of Guillain-Barré have been detected after 12.8 million doses of Johnson & Johnson vaccine were administered
Cardiovascular Drugs Do Not Impact COVID-19 Outcomes
Authors say patients even with COVID-19 should continue taking cardiovascular drugs as prescribed